CANGRELOR Chemical Properties

Boiling point:

979.0±75.0 °C(Predicted)

Density 

2.08

pka

0.82±0.50(Predicted)

Safety Information

Hazardous Substances Data

163706-06-7(Hazardous Substances Data)

CANGRELOR Usage And Synthesis

Uses

Anti-platelet agent.

Uses

Cangrelor is a P2Y12 inhibitor used as an antiplatelet drug for intravenous application.

Definition

ChEBI: A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.

Clinical Use

Direct P2Y12 platelet receptor antagonist:

Antiplatelet for patients undergoing a PCI

Metabolism

Cangrelor is deactivated rapidly in the plasma by dephosphorylation to form its main metabolite, a nucleoside. Following a 2 micrograms/kg/min infusion of [3 H] cangrelor, 58% was found in urine and the remaining 35% was found in faeces, presumably following biliary excretion.

CANGRELOR(163706-06-7)Related Product Information

• VILAZODONE
• Bortezomib
• Liraglutide
• 2-METHYLTHIOADENOSINE 5-MONOPHOSPHATE
• CLODRONIC ACID
• 2-methylthioadenosine
• (dichloromethyl)phosphonic acid
• CANGRELOR